Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
- Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
- Identify untapped treatment scenarios and key competitors to aid trial design.
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
- Discover untapped populations to expand product share and drive strategic decisions.
- Where is my product positioned versus that of competitors in the treatment journey?
- What are physicians’ most frequent treatment sequences; who is benefiting, and how can I defend my asset’s share and position?
- What are the market-relevant treatment scenarios according to oncology experts?
- How can I optimize trial design and ensure a competitive edge for my pipeline asset?
- Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (EU5)
Author(s): Swati Tyagi, M.Sc, MBA
Swati Tyagi, is a Senior Business Insight Analyst in the oncology team at the Decision Resources Group.
She comes with 8 years of work experience from the life sciences market research industry. She has in-depth expertise in competitive intelligence, secondary and primary research, and strategic projects across multiple oncology indications. Prior to joining the company, she was a delivery manager in a market research organization, where she was handling a major client engagement account and a dedicated team of senior and business analysts working for the specialty medicine brands of the client. She holds an M.Sc in biotechnology and MBA from Amity University, India.